Pfizer and BioNTech announced on Thursday it would soon begin a Phase 3 trial for its combined flu and COVID-19 mRNA vaccine following "positive" results from its Phase 1/2 study. Phase 1 and 2 trials are meant to evaluate if a new drug or treatment is both safe and effective. An official for Pfizer said Thursday they were "encouraged" by the results they've seen so far with their combined flu and COVID-19 vaccine. The company said the results indicated the shot had a safety profile comparable to its standalone COVID-19 vaccine. “This vaccine has the potential to lessen the impact of two respiratory diseases with a single injection and may simplify immunization practices for provide
Hence then, the article about combined covid flu vaccine from pfizer biontech moving to late stage testing was published today ( ) and is available onThe Hill ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( Combined COVID-flu vaccine from Pfizer, BioNTech moving to late-stage testing )